Actively Recruiting
Study of ALN-4324 to Improve Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Led by Alnylam Pharmaceuticals · Updated on 2026-08-12
24
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in adults with Type 2 Diabetes Mellitus T2DM. The study is a randomized, double-blind, placebo-controlled Phase 2 trial focusing on patients aged 18 to 65 years with T2DM, investigating how ALN-4324 may influence insulin function compared to placebo. Participants will receive a single subcutaneous dose of either ALN-4324 or a placebo. The study uses a parallel assignment model with triple masking to compare the effects of the investigational drug and placebo. The primary treatment period extends up to 3 months, with additional monitoring extending up to 9 months to assess safety and secondary outcomes. During the study, participants will undergo assessments including measurements of insulin sensitivity M-value, glucose production, and hemoglobin A1c levels at baseline and throughout follow-up visits up to 6 or 9 months. Researchers will track adverse events and changes in metabolic markers to understand treatment effects. The total participation period spans several months, with regular visits to monitor health and study progress.
CONDITIONS
Brief Title
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
